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Abstract
Background
Opioid use is associated with increased incidence of infectious diseases. Although experi-
mental studies have shown that opioids affect various functions of immune cells, only limit-
ed data are available from human studies. Drug use is an important risk factor for HIV
transmission; however no data are available whether heroin and/or methadone modulate
immune response. Therefore, we examined the effect of heroin and methadone use among
HIV-infected individuals on the production of cytokines after ex vivo stimulation with
various pathogens.
Methods
Treatment naïve HIV-infected individuals from Indonesia were recruited. Several cohorts of
individuals were recruited: 1) using heroin 2) receiving methadone opioid substitution 3)
using heroin over 1 year ago and 4) controls (never used opioids). Whole blood was stimu-
lated withMycobacterium tuberculosis, Candida albicans and LPS for 24 to 48 hours. Cyto-
kine production (IL-1 β, IL-6, IL-10, IFN-α, IFN-γ and TNF-α) was determined using
multiplex beads assay.
Results
Among 82 individuals, the cytokine levels in unstimulated samples did not differ between
groups. Overall, heroin users had significantly lower cytokine response after exposure to
LPS (p<0.05). After stimulation with eitherM. tuberculosis or C. albicans the cytokine pro-
duction of all groups were comparable.
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Conclusion
The cytokine production after exposure to LPS is significantly down-regulated in HIV-in-
fected heroin users. Interesting, methadone use did not suppress cytokine response, which
could have implications guidelines of opioid substitution.
Introduction
Opioid use is associated with increased incidence of infectious diseases. Variables, such as shar-
ing needles, nutrition status and homelessness, can influence the frequency of infections, but
studies also suggest that immune modulating effects of opioids are a major factor in the in-
creased susceptibility to various infectious agents [1–8]. More specifically, opioids have shown
to modulate several aspects of the immune system.
In both human and animal studies, opioid use has been associated with increased suscepti-
bility to microbial infections, including bacterial infections such as staphylococci, streptococci
and more specifically Escherichia coli, Salmonella typhimurium andMycobacterium tuberculo-
sis, the fungi Candida albicans, the parasite Toxoplasma gondii, and viruses such as the herpes
virus and Friend leukemia virus [7]. In addition, there is a high risk of blood-born infectious
diseases when unsterile needles are used to inject drugs, such as endocarditis, cellulitis, sepsis,
hepatitis C and human immunodeficiency virus (HIV) [6]. Injecting drug use (IDU) is respon-
sible for HIV infections in 10% of all cases worldwide, and 30% of cases outside Africa [1]. IDU
is not only a risk factor for HIV transmission, but it may also change the natural course of HIV
infection, for instance because of co-infections, nutritional deficiencies and/or the immune
modulating properties of opioids.
Experimental studies have shown that binding of opioids to the opioid μ-receptors of im-
mune cells affects the function of these cells in various ways. In vitro and animal experiments
have shown that opioids modulate phagocytosis, chemotaxis, cytokine response and activity of
immune cells; which could have detrimental results for the cellular immunity [6,7]. On the
other hand, other studies suggest that the effects of opioids on the immune system are not nec-
essarily deleterious; cells exposed to endogenous opioids in vitro increased natural killer cell ac-
tivity [9].
The regulation of immune and inflammatory responses is dependent on the functions of cy-
tokines, which is especially important in individuals with an already compromised immune
function, such as HIV-infected individuals. The effects of opioids on cytokine production have
been investigated in both in vitro and animal experiments [10–19], but only little information
is available on in vivo exposure in humans. In addition, the data from previous studies have
shown contradicting results. For example the production of IFN-γ can be enhanced [10] or
suppressed [11] by various opioids in in vitro studies, whereas in animal experiments the IFN-
γ production is often diminished after exposure to opioids [17,18]. The production TNF-α is
mostly suppressed by opioids [13,15,16], but some studies show no effect [14] or even an in-
crease in TNF-α [12]. Opioids reduce the IL-8 production [13,19], whereas IL-1β production is
often enhanced [12,19]. The differences in results might be explained by experimental set-up,
type of cells or animals used, and type of opioid.
Most studies use morphine to test the effects of opioids on immune system. Only limited
data are available from human studies; in most of these studies opioids are used for pain relief,
either post-surgery or during cancer treatment [20–24]. The main findings of these studies
were that morphine suppressed natural killer cell activity, reduced mitogen responses and
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decreased lymphoproliferation. One study examined the effects of morphine in healthy volun-
teers [25]: continuous exposure to morphine over a period of 36 hours resulted in suppression
of natural killer cell cytotoxicity as well as IFN-γ stimulated and antibody-dependent cytotox-
ity. All these study suggests that morphine administration can cause measurable suppression of
the immune system.
Heroin and methadone are however more commonly associated with HIV infection. As the
different opioids are known to have different affinity for the opioid receptors [26–28], one may
hypothesize that they exert different immune modulating effects. Only two human studies ex-
amined the immunological effects of heroin or methadone. One study compared the effects of
methadone and buprenorphine (as opioid substitution) in drug users and found no difference,
but cytokine levels were significantly depressed compared to controls [29]. Azarang et al com-
pared the ex vivo cytokine production after stimulation of whole blood between heroin users
and healthy controls and found that heroin addicts produce less IFN-γ and more interleukin
(IL)10 after stimulation with lipopolysaccharides (LPS) [30]. Even though drug use is not un-
common among HIV-infected individuals, no data are available regarding the effects of heroin
or methadone on the immune response in HIV. In the present study, we examined therefore
the effect of heroin and methadone use among HIV-infected individuals on the production of
cytokines after ex vivo stimulation with various pathogens relevant in the HIV patients.
Methods
Study setting and population
For this study, we included HIV-infected adults (>16 years) from several settings in West-
Java, Indonesia; an HIV clinic, a methadone clinic and the community. The collaboration with
the clinics and the community was part of a five-year programme (2006–2011) called ‘IM-
PACT’, aimed to improve prevention, control and treatment of HIV among injecting drug
users in West-Java, Indonesia [31]. In these clinics, people with and without a history of IDU,
who are at risk for HIV infection or who present with signs and symptoms suggesting HIV/
AIDS are counselled and tested for HIV. All testing is voluntary and informed consent is ob-
tained from all study participants. HIV-infected patients are characterised and followed pro-
spectively in a cohort study. To contact individuals in the community we collaborated closely
with Rumah Cemara; a local NGO focussing on increasing the quality of life for people with
HIV/AIDS and people who use drugs. All subjects selected for this study were antiretroviral
treatment naïve HIV-infected and had no signs of active infections, such as acute hepatitis, ac-
tive tuberculosis or oral thrush. Participants were not tested for (chronic) hepatitis C infection
or latent tuberculosis. Individuals had to fit the inclusion criteria of one of the four groups: 1)
Active drug users: used heroin in the last 30 days; 2) Methadone clients: received methadone
maintenance treatment (MMT) in the last 30 days; 3) Former users: used heroin or methadone
over one year ago; 4) Controls: never used heroin or methadone. All participants were in-
formed on the study and signed an informed consent. Data on demographic factors, history of
drug use, co-morbidity, self-reported tuberculosis treatment and history of ART were collected
through interview with standardized questionnaires. In addition, blood was collected for vari-
ous purposes, including CD4 cell count, general haematology, flow cytometry and cell stimula-
tion assays. At the time of this study, antiretroviral therapy (ART) was indicated in Indonesia
for patients presenting with WHO clinical stage IV or a CD4 count less than 200 cells/μl in ac-
cordance with WHO guidelines from 2006. Since 2004, ART can be accessed free of charge in
Indonesia.
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Stimulation assay
Cytokine production was examined after whole blood stimulation with various pathogens,
namely killed Candida albicans andMycobacterium tuberculosis as infection with these are
often associated with HIV and LPS isolated from Escherichia coli as a TLR4 agonist. Briefly, ve-
nous blood was drawn into 5-mL endotoxin-free lithium-heparin tubes (Vacutainer, BD Bio-
sciences) and samples were processed within 4 hours. Blood was diluted 1:5 with culture
medium only (RPMI Dutch modified) or in combination with either conidia of heath killed C.
albicans (106 cells/ml),M. tuberculosis (10 μg/ml), LPS isolated from E. coli (10 ng/ml). After
24 or 48 hour incubation, blood cultures were centrifuged at 1700rpm for 10 min and superna-
tants were stored at −20°C until assayed. During this period opioid levels were not measured,
nor was the opioid level maintained during incubation. The expression of cytokines IL-1 β, IL-
6, IL-10, IFN-α, IFN-γ and TNF-α were measured using a multiplex beads assay (Merck Milli-
pore, Billerica, MA, USA) according to the manufacturer's instructions. The detection limit for
the cytokine production was 32pg/μl for IL-1β and IL-6 and 3.2pg/μ for and IL-10, IFN-α,
IFN-γ and TNF-α. Based on previous testing we measured the production of IL-1β and IL-6 in
24 hours samples and IL-10, IFN-α, IFN-γ and TNF-α in 48 hour samples.
Statistical analyses
Subjects with CD4 cell counts below 100cells/μl were excluded from statistical analyses. All cy-
tokine levels after stimulation were corrected for the amount of CD4 cells and the unstimulated
levels. The production of cytokines was compared between groups using Kruskul-Wallis and
MannWhitney analyses. Results were found statistically significant at a level of 0.05, resulting
in a p-value of 0.016 after Bonferroni adjustment for multiple tests. All statistical analysis was
performed using the Statistical Product and Services Solutions package (SPSS) version 18.0 and
GraphPad Prism version 5.0.
Results
We included a total of 82 ART-naïve HIV-infected individuals with CD4 cell counts above
100cells/μl (Table 1). Overall, controls were slightly younger than the drug user groups
(Table 1), but the groups did not differ in CD4 cell counts (p = 0.13, Table 1).
Whole blood from these individuals was stimulated with various pathogens, namely C.albi-
cans,M.tuberculosis and LPS isolated from Escherichia coli. The cytokine production of unstimu-
lated samples was low and did not differ between groups; the median cytokine level was 32pg/μl
for IL-1β (p = 0.466), 32.6pg/μl for IL-6 (p = 0.845), 6.7pg/μl for IFN-α (0.947), 4.0pg/μl for
IFN-γ (0.431), 3.2pg/μl IL-10 (0.625) and 11.9 pg/μl for TNF-α (p = 0.382).
The results from the stimulated samples showed that generally the cytokine production was
significantly lower in heroin users (Fig 1) after exposure to LPS. Interesting the same was not
observed after stimulation with C. albicans (Fig 2) andM. tuberculosis (Fig 3). Analysing the
effect LPS exposure, significant less IL-1β, IL-6, TNF-α and IFN-γ production was found in
heroin users (Fig 1). The production of these cytokines in MMT and previous users was
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comparable to the controls (Fig 1). No differences were found in the production of IL-10 after
exposure to LPS. Stimulation with C. albicans from both heroin users and previous users
seemed to produce less IL-1β and IL-6 than from controls; however these differences were not
significant (Fig 2). Also the production of the other cytokines was comparable between all
groups after exposure to C. albicans. Compared to controls, the IL-6 production after stimula-
tion withM. tuberculosis was lower in heroin users (not significant p = 0.73) and previous
users (p = 0.012) (Fig 3). Also the production of IL-1β and TNF-α seems to have the same
trend, but the differences were not statistically significant. Overall, not clear differences were
found after stimulation withM. tuberculosis (Fig 3). The production of IFN-α was low in all
stimulated samples and therefore these data are not shown.
Discussion
In this study we show that the cytokine production is significantly down-regulated in HIV-in-
fected heroin users compared to HIV-infected individuals who do not use opioids. Interesting,
the altered cytokine production was only observed when cells were exposed to LPS but not to
M. tuberculosis or C. albicans.
We found that LPS-induced cytokines were affected by heroin use, whereas C. albicans and
M. tuberculosis-induced cytokines were not. One could argue that the receptors and pathways
involved in candida (C-type lectin receptors) and tuberculosis (TLR 2 and NOD2) are less af-
fected by opioids. However, previous studies have also found associations between opioids and
these receptors [32–34]. In addition, the cytokine levels after stimulation withM. tuberculosis
were relatively high and therefore might mask a difference between groups due to a ceiling ef-
fect. In the present study we only found effects of LPS, which is a specific agonist for TLR4;
therefore our results suggest that opioids may affect mainly the TLR4-dependent cytokine pro-
duction. A binding site for opioids on the TLR4 protein complex has indeed been demonstrat-
ed [35]. Studies have furthermore shown that both opioid agonists and antagonists alter the
expression of TLR4 [36,37] or affect LPS signalling via the TLR4 signalling pathway [38],
which strengthen the data of our study. The latter study showed that morphine alone only
weakly increased TLR4 activation, but it significant inhibited TLR4 signalling after LPS stimu-
lation. Interesting naltrexone (a μ-opioid antagonist) also significantly inhibited LPS-induced
TLR4 activation [38]. Apart from its effect on monocyte/ macrophages, animal studies also in-
dicate that morphine influences the production of TNF-α in mast cells in a TLR4-dependent
manner [39]. Interestingly, the interaction between opioids and TLR4 may also work in the op-
posite direction, as activation of TLR4 can increase the production of endogenous opioids,
such as β-endorphin [40]. Furthermore, some studies find that stimulation of TLR4 affects the
opioid-induced responses, such as incubated cue-induced heroin-seeking and morphine
Table 1. Characteristics of ART-naïve HIV-infected individuals in this study (n = 82).
Heroin users(n = 17) MMT(n = 17) Former users(n = 17) Controls(n = 31) p-value*
Male (%) 82.4 94.1 88.2 77.4 0.462
Median age (IQR) 32 (29–37) 33 (30–35) 32 (30–34) 28 (22–32) 0.006
Median Hb (IQR) 14.7 (13.2–16.0) 14.0 (12.9–15.1) 15.6 (14.8–16.2) 14.8 (13.2–15.9) 0.039
Median CD4 cell count (IQR) 411 (225–651) 240 (169–490) 377 (258–615) 283 (173–399) 0.13
Heroin users: used heroin in the last 30 days. MMT: individuals receiving methadone maintenance treatment (MMT) in the last 30 days. Former users:
used heroin or methadone over one year ago. Controls: never used heroin or methadone.
*All groups were compared using Kruskal-Wallis analyses. ART: antiretroviral therapy, IQR: interquartile range; Hb: haemoglobin
doi:10.1371/journal.pone.0122822.t001
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Fig 1. The concentration of IL-1B (A), IL-6 (B), TNF-α (C), IFN-γ (D) and IL-10 (E) after ex vivo stimulation with LPS of E.coli in various groups of
ART-naïve HIV-infected individuals; individuals who used heroin in last 30 days (circles), individuals receivingmethadonemaintenance treatment
(MMT: squares), individuals who used heroin over one year ago (former users: triangles) and those who never used opioids (controls: reversed
triangles). The level of cytokines was corrected for baseline level and number of CD4 cells (and given in pictogram per 105 cells). *Statistically significant
difference (p< 0.016 after Bonferroni adjustment for multiple tests). MMT: methadonemaintenance treatment; ART: antiretroviral therapy.
doi:10.1371/journal.pone.0122822.g001
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tolerance [41,42], whereas others find no clear link [43]. Our study is in line with these studies,
showing decreased signalling of TLR4 after LPS stimulation in individuals exposed to opioids.
Even though we did not stimulate with the whole pathogen of E.coli we believe our results are
Fig 2. The concentration of IL-1B (A), IL-6 (B), TNF-α (C), IFN-γ (D) and IL-10 (E) after ex vivo stimulation withCandida albicans in various groups of
ART-naïve HIV-infected individuals; individuals who used heroin in last 30 days (circles), individuals receivingmethadonemaintenance treatment
(MMT: squares), individuals who used heroin over one year ago (former users: triangles) and those who never used opioids (controls: reversed
triangles). The level of cytokines was corrected for baseline level and number of CD4 cells (and given in pictogram per 105 cells). *Statistically significant
difference (p< 0.016 after Bonferroni adjustment for multiple tests). MMT: methadonemaintenance treatment; ART: antiretroviral therapy.
doi:10.1371/journal.pone.0122822.g002
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Fig 3. The concentration of IL-1B (A), IL-6 (B), TNF-α (C), IFN-γ (D) and IL-10 (E) after ex vivo stimulation with Mycobacterium tuberculosis in
various groups of ART-naïve HIV-infected individuals; individuals who used heroin in last 30 days (circles), individuals receivingmethadone
maintenance treatment (MMT: squares), individuals who used heroin over one year ago (former users: triangles) and those who never used
opioids (controls: reversed triangles). The level of cytokines was corrected for baseline level and number of CD4 cells (and given in pictogram per 105
cells). *Statistically significant difference (p< 0.016 after Bonferroni adjustment for multiple tests). MMT: methadone maintenance treatment; ART:
antiretroviral therapy.
doi:10.1371/journal.pone.0122822.g003
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still relevant to exposure to E.coli, as the TLR4 pathway is one of the most important pathways
for this pathogen.
In addition to the mechanisms described above, bacterial translocation in opioid users
might also contribute to our findings, as animal studies have shown that morphine increases
bacterial translocation [44–46]. Opioid induced intestinal permeability may result in more ex-
posure to microorganism and endotoxins; continuous exposure could result in the well-known
process of endotoxin tolerance [47], which may explain our findings of reduced ex vivo produc-
tion of pro-inflammatory cytokines after LPS exposure in heroin users. While endotoxin toler-
ance has been thought of as a protective mechanism against septic shock and ischaemia, its
incidence is associated with high risks of secondary infections [48]. Various molecular mecha-
nisms have been described that underlie the development of endotoxin tolerance, including de-
fects in the TLR4 signalling pathway, activation of SOCS molecules, stimulation of anti-
inflammatory cytokines such as IL-10, or epigenetic regulation [47–49]. In addition to opioids,
HIV infection may increase gut permeability and exposure to endotoxins [50,51]. Our data
show that response to LPS is diminished which could therefore be due to translocation of bac-
teria, especially since all study subjects were HIV positive.
In addition, the opioid-induced immunomodulation may be affected by other factors such
as chronic hepatitis C infection. In this study we excluded individuals with signs of acute hepa-
titis but we did not test for (chronic) hepatitis C infection. Hepatitis C is highly prevalent
among injecting drug users and we have previous shown that up to 90% of HIV-infected inject-
ing drug users in Indonesia are seropositive for hepatitis C [52]. Previous studies have shown
worse clinical outcomes among HIV-infected individuals with hepatitis C antibodies [53–58].
However, the relation between hepatitis C infection and HIV progression prior to ART re-
mains unclear [53–56,59]; the effects of hepatitis C seems to be more pronounced among pa-
tients receiving ART [59,60]. A recent study examined the relation between hepatitis C and
circulating cytokine levels [50]. Overall, cytokine levels were significantly higher in individuals
co-infected with HIV and hepatitis C, while no data were presented about opioid use [50].
Since hepatitis C is strongly correlated with injecting drug use, it is therefore difficult to distin-
guish between the effects of opioids and hepatitis C.
Only one other study analysed the influence of heroin or morphine use on the cytokine re-
sponse [30], showing that HIV-negative heroin users produce less IFN-γ and more IL-10 after
stimulation with LPS. Interesting, this difference was larger for heroin users compared to mor-
phine. In line with these results, we also found a decrease of IFN-γ after LPS stimulation; how-
ever we did not find an increase of IL-10. We found a lot of variance in the production of IL-
10, which might have led to not finding a statistically significant difference. Furthermore, we
also found a significant difference between heroin and methadone users. We have previous
found similar results on the expression of HIV co-receptors [61]. Clinical and illicit opioids,
such as morphine, methadone and heroin, exert their effects primarily through the μ-opioid re-
ceptor, but all with different affinity and some also bind to other opioid receptors [26–28,62].
In addition, multiple isotypes of the μ-opioid receptor exists, with differences in ligand binding
affinity, rates of internalization and resensitisation. This may explain the differences that are
observed when heroin, morphine or methadone are used.
Opioid-induced immunosuppression has shown to be mediated either directly via immune
cells or via the central nervous system. In this study we focussed on the peripheral aspects of
opioid-induced immunomodulation by using ex vivo stimulation of whole blood. However, the
immune effects of opioids in vivomay also be affected by the central nervous system, as previ-
ously found in animal experiments [63,64]. The effects of opioids are especially important
among HIV-infected individuals, as chronic opioid use has been shown to modulate HIV pro-
gression and facilitate HIV associated neurocognitive dysfunctions [52,65]. Among other
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aspects, opioids may modulate epigenetic and transcriptional regulation of the μ-opioids recep-
tor; this may in turn alter the overall physiological effect of opioids which could be important
in HIV disease progression [65].
In our study we determined drug use based on interviews and did not perform toxicological
tests, which could perhaps result in a bias. However, we worked closely together with employ-
ees of a local NGO, who have been in close contact with our subjects for years. In addition,
drug test will only show recent use of opioids (up to four days) and therefore might not be reli-
able in identifying active users that did not use in the previous couple of days. In addition, we
do not have HIV viral loads of our study population, which might also affect the production of
cytokines. However, we have previously shown that the viral load among people with and with-
out a history of injecting drug use did not differ [52]. Another factor that may influence the cy-
tokine production is HIV subtype, on which we have information in this population. In
addition, drug users might have had a different immune status at inclusion. However, in unsti-
mulated samples the cytokine levels were low in all groups. This indicates an inactive immune
status of cells in all groups, and can therefore not explain the differences we show.
In conclusion, this is the first study to examine the immonumodulating effects of heroin
and methadone in HIV-infected individuals. We show that heroin use decreases the cytokine
response to LPS, but not toM. tuberculosis and C. albicans. Especially in HIV-infected individ-
uals these immunomodulating effects of opioids may have deteriorating effects and increase
the risk of secondary infections.
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